A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure

The standard of care for patients with chronic hepatitis C virus (HCV) infection is a combination of direct-acting antiviral agents (DAA). Although interferon-free DAA-based regimens are highly successful in the vast majority of patients with HCV infection, treatment is nevertheless unsuccessful in some patients. European Association for Study of Liver Recommendations 2016 recommend that retreatment be based on an interferon-free combination, including sofosbuvir (SOF) as a backbone (because of its higher barrier to resistance than other agents), plus one to three other DAAs, ideally with no cross-resistance with the previously administered drugs, plus ribavirin (RBV) for 12 –24 weeks.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research